SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: February 28, 2010
(Date of earliest event reported)
VASOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-18105 11-2871434
------- ----------
(State or other (Commission File (IRS Employer
jurisdiction of incorporation) Number) Identification No.)
180 Linden Avenue, Westbury, New York 11590
--------------------------------------------------------------------
(Address of principal executive offices) (zip code)
Registrant's telephone number, including area code (516) 997-4600
--------------
-------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
[ ] Pre-commencement communications pursuant to Rule 13e-4c under the Exchange
Act (17 CFR 240.13e-4c)
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On February 28, 2010 we entered into an amendment (the "Amendment") to our
Supplier Agreement with Living Data Technology Corporation ("Living Data"). A
copy of the Amendment is filed as Exhibit 99.1 to this report and is
incorporated in its entirety.
The Amendment terminated the provisions of the Supplier Agreement pursuant
to which Living Data had acted as the exclusive supplier to the Company of the
EECP Systems distributed by the Company. It further provided for the sale by
Living Data to the Company of a number of EECP Systems for a total purchase
price of $469,450, payable through the issuance of 7,824,167 shares of common
stock of the Company. The common stock issued was valued at $.06 per share, the
closing price of the common stock on February 11, 2010, the date on which Living
Data and the Company agreed to the Company's purchase of the Systems.
The Amendment also provided for Living Data to cooperate fully with the
Company in the Company's efforts to obtain directly from the manufacturer
thereof the Systems previously furnished to the Company by Living Data.
ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES
See Item 1.01 above.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
99.1 Amendment dated as of February 28, 2010 to the Supplier Agreement
dated June 21, 2007 between Living Data Technology Corporation
and Vasomedical, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VASOMEDICAL, INC.
Date: March 4, 2010
By: /s/ Jun Ma
--------------------------------
Jun Ma
President and Chief Executive Officer